| Followers | 236 |
| Posts | 15415 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Friday, August 28, 2020 2:13:49 PM
Are you actually thinking that this small quantity of vaccines (5) would be sufficient to meet the demands of the specials program?
I'm sure we'd both agree that the London capacity certainly wouldn't be enough to meet the bigger UK/EU demand.
I'd think it would be better to have the Sawston facility ready to manufacture a much larger quantity of vaccines before they seek UK approval. And with top line intended to be completed sometime in September, they would likely seek UK approval soon after.
And if instead, they were to seek approval based on the teensy weensy lab space they rent out in London, I'd think the MHRA would be hesitant to approve them. I think the MHRA instead expects them to prove they have the ability to manufacture to at least meet the needs of the market. It was also very helpful that the Cambridgeshire & Peterborough Combined Authority offered them the "SPECIAL PURPOSE COMPETITIVE LOAN" amounting to additional funds of $1.77 million to help facilitate their build out. I'm betting they actually submitted for that loan about two years ago. And to think, it took this long to WIN it.
But if you still persist in thinking NWBO is a scam, then I could see why you'd think producing only five vaccines a month would be adequate for the company. I mean, why spend any money building out a much larger facility that you're already paying rent on to make more like a couple hundred vaccines a month, if all you care about, really, is having enough to make your pay check?
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
